These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19686257)

  • 1. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies.
    Antoniou C; Moustou AE; Vergou T; Stratigos A; Kalambokas A; Katsambas AD
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):356-7. PubMed ID: 19686257
    [No Abstract]   [Full Text] [Related]  

  • 2. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Up-date on the use of infliximab in dermatology. Introduction].
    Sánchez-Carazo J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
    [No Abstract]   [Full Text] [Related]  

  • 4. Early videocapillaroscopic changes of the psoriatic skin after anti-tumour necrosis factor alpha treatment.
    De Angelis R; Gasparini S; Bugatti L; Filosa G
    Dermatology; 2005; 210(3):241-3. PubMed ID: 15785057
    [No Abstract]   [Full Text] [Related]  

  • 5. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab and nephrotic syndrome.
    Chin G; Luxton G; Harvey JM
    Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurological symptoms following infusion of infliximab].
    Bebe AC; Harboe KM; Nøjgaard C
    Ugeskr Laeger; 2012 Oct; 174(40):2388-90. PubMed ID: 23031302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multiple lesions of focal cutaneous mucinosis: a side-effect of anti-TNF alpha therapy?].
    Duparc A; Gosset P; Lasek A; Modiano P
    Ann Dermatol Venereol; 2010 Feb; 137(2):140-2. PubMed ID: 20171438
    [No Abstract]   [Full Text] [Related]  

  • 10. Consecutive use of different biological therapies in the treatment of psoriasis.
    Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
    Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
    [No Abstract]   [Full Text] [Related]  

  • 11. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.
    Smith CH; Anstey AV; Barker JN; Burden AD; Chalmers RJ; Chandler DA; Finlay AY; Griffiths CE; Jackson K; McHugh NJ; McKenna KE; Reynolds NJ; Ormerod AD;
    Br J Dermatol; 2009 Nov; 161(5):987-1019. PubMed ID: 19857207
    [No Abstract]   [Full Text] [Related]  

  • 12. New development in the treatment of psoriasis--infliximab.
    Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric MALT lymphoma in a patient receiving infliximab for psoriasis.
    Girard C; Guillot B; Bessis D
    Br J Dermatol; 2008 Aug; 159(2):497-8. PubMed ID: 18547313
    [No Abstract]   [Full Text] [Related]  

  • 14. [Body-weight changes in psoriatic patients on systemic treatment].
    Forien M; Mahé E; Sin C; Marchal A; Sigal ML
    Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.
    Fairhurst DA; Sheehan-Dare R
    Clin Exp Dermatol; 2009 Apr; 34(3):421-2. PubMed ID: 19309375
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab-induced lichen planopilaris.
    Fernández-Torres R; Paradela S; Valbuena L; Fonseca E
    Ann Pharmacother; 2010 Sep; 44(9):1501-3. PubMed ID: 20702759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD; Castro LG; Romiti R
    Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
    [No Abstract]   [Full Text] [Related]  

  • 20. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
    Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
    Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.